Skip to main content

Table 5 Key methodological characteristics of HTAs of biosimilars

From: Health technology assessment of biosimilars worldwide: a scoping review

HTA reports

Immunogenicity was considered

Risk of switching/interchangeability was considered

Extrapolation of one or more condition was considered

Educational approach about biosimilars was considered

Statement in favour, against or not declared about the adoption/reimbursement of biosimilar

Statement in favour

Statement against

Not declared

Full HTA

(n = 2)

1

1

1

1

2

0

0

Mini-HTA

(n = 4)

4

4

4

4

4

0

0

Rapid review

(n = 64)

39

13

42

14

51

0

13

  1. HTA health technology assessment